Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1088 · 1 trial · 1 indication
Cmax of ABBV-1088
Tmax of ABBV-1088
Terminal phase elimination rate constant (beta) of ABBV-1088
Terminal phase elimination half-life of ABBV-1088
AUCt of ABBV-1088
AUCinf of ABBV-1088
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| Group 1- ABBV-1088 Dose A | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose A on day 1 |
| Group 1- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 2- ABBV-1088 Dose B | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose B on day 1 |
| Group 2- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 3- ABBV-1088 Dose C | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose C on day 1 |
| Group 3- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 4- ABBV-1088 Dose D | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose D on day 1 |
| Group 4- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 5- ABBV-1088 Dose E | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose E on day 1 |
| Group 5- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 6- ABBV-1088 Dose F | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose F on day 1 |
| Group 6- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Name | Type | Description |
|---|---|---|
| Drug: ABBV-1088 | DRUG | • Oral Capsule |
| Drug: Placebo for ABBV-1088 | DRUG | • Oral Capsule |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at screening. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG Exclusion Criteria: * History of card...
ABBV-1088 is an investigational small molecule drug being developed by AbbVie Inc. It is in Phase 1 clinical development. The specific disease or condition it is intended to treat has not been disclosed. It has been studied in a completed Phase 1 trial in healthy adult volunteers.
ABBV-1088 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker symbol ABBV. AbbVie is the sponsor of the clinical program for this investigational small molecule.
ABBV-1088 is in Phase 1 clinical development. One Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA for any indication.
ABBV-1088 has been evaluated in one completed Phase 1 trial, NCT06414798. The study assessed the safety, tolerability, and pharmacokinetics of an oral dose of ABBV-1088 in 60 healthy adult participants in the United States. It was randomized, double-blind, and controlled.
Yes, ABBV-1088 is also referred to as Drug: ABBV-1088. Both names refer to the same investigational small molecule being developed by AbbVie Inc. under the ticker ABBV.